Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SCB-1019/SCB-1019T in Healthy Adults
NCT06194318Phase 1Completed
- Sponsor
- Clover Biopharmaceuticals
- Start
- Dec 2023
- Primary completion
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes, Split/Subunit Vaccines, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SCB-1019 in respiratory syncytial virus infection (RSV) (14 arms), sponsored by Clover Biopharmaceuticals. Primary endpoints: Reactogenicity of SCB-1019, SCB-1019T compared with AREXVY vaccine at 7 days, Safety and tolerability of SCB-1019, SCB-1019T compared with AREXVY vaccine at 28 days and 2 more. Started Dec 2023; status: completed.
02
Drugs
SCB-1019
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06194318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06194318.